A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

NCT05498428 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

520

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-small-Cell Lung

Interventions

DRUG: Amivantamab
DRUG: Lazertinib
DRUG: Carboplatin
DRUG: Pemetrexed
DRUG: Direct Oral Anticoagulant (DOAC)
DRUG: Low Molecular Weight Heparin (LMWH)

Sponsor

Janssen Research & Development, LLC